Financials
Reported figures only · latest: Q4 2025
USD · IFRS
Revenue by quarter
Q2 24 Q2 25
Source: SEC XBRL filings
· latest filing
The long view
Fiscal years as reported · SEC XBRL filings, IFRS
Revenue and net income12 fiscal yearsShow the numbers
| Year | Revenue | Net income |
|---|
| FY25 | $1.2M | −$2M |
|---|
| FY24 | $28.9M | −$9.2M |
|---|
| FY23 | $4.8M | −$60.6M |
|---|
| FY22 | $0 | −$25M |
|---|
| FY21 | $0 | −$27.1M |
|---|
| FY20 | - | −$30M |
|---|
| FY19 | - | −$25.4M |
|---|
| FY18 | - | −$23M |
|---|
| FY17 | - | −$24.4M |
|---|
| FY16 | - | −$15.8M |
|---|
| FY15 | - | −$14.4M |
|---|
| FY14 | - | - |
|---|
MarginsShare of revenue- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|
| FY25 | 80.5% | −871.8% | −171.7% |
|---|
| FY24 | 68% | −70.5% | −31.9% |
|---|
| FY23 | 23.1% | −1035.3% | −1262.8% |
|---|
| FY22 | - | - | - |
|---|
| FY21 | - | - | - |
|---|
| FY20 | - | - | - |
|---|
| FY19 | - | - | - |
|---|
| FY18 | - | - | - |
|---|
| FY17 | - | - | - |
|---|
| FY16 | - | - | - |
|---|
| FY15 | - | - | - |
|---|
| FY14 | - | - | - |
|---|
Free cash flowOperating cash flow minus capital expenditureShow the numbers
| Year | Free cash flow |
|---|
| FY25 | −$8.1M |
|---|
| FY24 | −$43.9M |
|---|
| FY23 | −$22.7M |
|---|
| FY22 | −$26.4M |
|---|
| FY21 | −$23.7M |
|---|
| FY20 | −$23.2M |
|---|
| FY19 | −$22.7M |
|---|
| FY18 | −$24.4M |
|---|
| FY17 | −$20.9M |
|---|
| FY16 | −$14.6M |
|---|
| FY15 | −$16.9M |
|---|
| FY14 | - |
|---|
Net margin vs the sectorMedian of Healthcare companies filing with the SEC- BioLineRx Ltd.
- Healthcare median
Show the numbers
| Year | BioLineRx Ltd. | Healthcare median |
|---|
| FY25 | −171.7% | −30.6% |
|---|
| FY24 | −31.9% | −47% |
|---|
| FY23 | −1262.8% | −58% |
|---|
| FY22 | - | −80.4% |
|---|
| FY21 | - | −71.9% |
|---|
| FY20 | - | −62.2% |
|---|
| FY19 | - | −46.3% |
|---|
| FY18 | - | −49.6% |
|---|
| FY17 | - | −45.9% |
|---|
| FY16 | - | −36% |
|---|
| FY15 | - | −38.4% |
|---|
| FY14 | - | −35.5% |
|---|